CRISPR Therapeutics AG
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRSPN.MX | NTLA | SANA | 6949.TW | SCTX | EDIT | |
|---|---|---|---|---|---|---|
| Market cap | 92.15B | 1.72B | 766.36M | 50.60B | 317.67M | 417.74M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -4.8 | -4.6 | — | -4.6 | -3.6 |
| Price/book | 3.0 | 2.4 | 5.0 | 19.7 | -0.3 | 4.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −20.19% | −0.08% | −36.79% | −89.40% | −14.60% | −6.47% |
| Today | 0.00% | +3.79% | +4.92% | −2.15% | +3.58% | +4.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All CRSPN.MX news ›CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
markets.businessinsider.com CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR The
CRISPR Therapeutics Q3 CASGEVY Revenue Reaches $99 Million
CRISPR Therapeutics (CRSP ) reported third-quarter 2026 results on November 2, 2026 for the quarter ended September 30, 2026, posting CASGEVY revenue of $99 million and a net loss of $111.4 million, compared with a $106.4 million loss a…
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and…
CRISPR Therapeutics GAAP EPS of -$1.15 misses by $0.15, revenue of $12.67M misses by $3.89M
CRISPR Therapeutics Q3 results show an EPS miss, a sharp revenue jump, and shares down 2%. - CRISPR Therapeutics press release (CRSP): Q3 GAAP EPS of -$1.15 misses by $0.15. - Revenue of $12.67M (+1323.6% Y/Y) misses by $3.89M.
CRISPR Therapeutics (NASDAQ:CRSP) and Ernexa Therapeutics (NASDAQ:ERNA) Head to Head Review
Posted by Mitch Edgeman on Nov 3rd, 2026 Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
CRISPR Therapeutics names CTO
CRISPR Therapeutics appoints Sivakesava Sakhamuri as CTO, adding 30 years of manufacturing and RNA therapeutics expertise. - CRISPR Therapeutics (CRSP) said on Monday that it appointed Sivakesava Sakhamuri as Chief Technical Officer,…
CRISPR Therapeutics Reports $12.7M Revenue and $111.4M Net Loss
TradingView CRISPR Therapeutics Reports $12.7M Revenue and $111.4M Net Loss CRISPR Therapeutics reported third-quarter 2026 revenue of $12.7 million and a net loss of $111.4 million. Collaboration revenue was $12.3 million, while cash,
CRISPR Therapeutics AG (CRSP) - What Are Analysts Saying About This Stock?
Check Out Our Latest Stock Report on CRSP Here are the key news stories impacting CRISPR Therapeutics this week: Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.…
CRISPR Therapeutics (NASDAQ:CRSP) Issues Earnings Results
MarketBeat CRISPR Therapeutics (NASDAQ:CRSP) Issues Earnings Results - CRISPR Therapeutics missed quarterly expectations: It reported an adjusted loss of $1.15 per share versus the $1.04 consensus loss estimate, while revenue of $12.67…
Needham maintains CRISPR Therapeutics at Buy, keeps price target at $82
TradingView Needham maintains CRISPR Therapeutics at Buy, keeps price target at $82 Needham maintained CRISPR Therapeutics at Buy and kept its price target at $82. The price target implies an upside of 64.0% from the Nov 2 clos
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com9
- stocktitan.net6
- fool.com5
- tradingview.com5
- marketscreener.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 57 articles, not a forecast.